Since 1989, Health Decisions has conducted more than 300 clinical trials, including more than 140 studies in women’s health indications and more than 20 studies of diagnostics. Health Decisions has a dual focus on clinical development in women’s health and diagnostics. The company’s initial focus on women’s health led to an extension into diagnostics more than a decade ago with a PMA study of a diagnostic for high-risk HPV. Regulatory approval and clinical adoption of the HPV diagnostic markedly improved screening for cervical cancer, enabling early detection that likely reduced the number of women whose HPV infections evolved into precancerous lesions and cervical cancers. Other Health Decisions successes include clinical development of a wide variety of contraceptives, including drugs, devices and drug/device combinations. Approval of these contraceptives has provided women with a greater selection of acceptable alternatives for managing their reproductive health. Successful development of women’s health diagnostics and novel contraceptives are but two examples of Health Decisions fulfilling its mission to improve health outcomes for women worldwide. Other Health Decisions studies have advanced clinical development of therapeutics and diagnostics in areas as diverse as vasomotor symptoms, pain management following childbirth, STIs, bacterial vaginosis, assessing risk of preterm birth and multiple sclerosis.